Inventor · disambiguated record
Jurgen Bajorath
Also filed as: BAJORATH JUERGEN · BAJORATH JURGEN
24 granted patents·10 pending applications·1,770 citations·filing 1992–2020
97Inventor score
Files withBRISTOL MYERS SQUIBB CO23CYTOKINE PHARMASCIENCES INC1GEMIN X BIOTECHNOLOGIES INC1GEN HOSPITAL CORP1KAROBIO AB1
Top patents by PatentIndex Score
34 records- 0198US6132992AExpression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cellBRISTOL MYERS SQUIBB CO·Filed 1995·Granted Oct 17, 2000·387 cites·54 claims
- 0298US5637481AExpression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cellBRISTOL MYERS SQUIBB CO·Filed 1993·Granted Jun 10, 1997·331 cites·22 claims
- 0397US7094874B2Soluble CTLA4 mutant moleculesBRISTOL MYERS SQUIBB CO·Filed 2001·Granted Aug 22, 2006·86 cites·42 claims
- 0496US6051228AAntibodies against human CD40BRISTOL MYERS SQUIBB CO·Filed 1998·Granted Apr 18, 2000·202 cites·17 claims
- 0595US7304033B2Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant moleculesBRISTOL MYERS SQUIBB CO·Filed 2002·Granted Dec 4, 2007·90 cites·32 claims
- 0695US6090914ACTLA4/CD28Ig hybrid fusion proteins and uses thereofBRISTOL MYERS SQUIBB CO·Filed 1994·Granted Jul 18, 2000·149 cites·7 claims
- 0794US7105166B1Soluble CTLA4 mutant molecules and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2000·Granted Sep 12, 2006·33 cites·12 claims
- 0894US6482919B2Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cellBRISTOL MYERS SQUIBB CO·Filed 2001·Granted Nov 19, 2002·68 cites·6 claims
- 0993US7700556B2Methods of treatment using CTLA4 mutant moleculesBRISTOL MYERS SQUIBB CO·Filed 2007·Granted Apr 20, 2010·14 cites·8 claims
- 1092US7455835B2Methods for treating immune system diseases using a soluble CTLA4 moleculeBRISTOL MYERS SQUIBB CO·Filed 2001·Granted Nov 25, 2008·57 cites·31 claims
- 1191US5876950AMonoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapyBRISTOL MYERS SQUIBB CO·Filed 1995·Granted Mar 2, 1999·115 cites·50 claims
- 1290US7829534B2Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant moleculesBRISTOL MYERS SQUIBB CO·Filed 2007·Granted Nov 9, 2010·16 cites·14 claims
- 1390US7439230B2Methods of treatment using CTLA4 mutant moleculesBRISTOL MYERS SQUIBB CO·Filed 2004·Granted Oct 21, 2008·22 cites·16 claims
- 1490US6312693B1Antibodies against human CD40Filed 1999·Granted Nov 6, 2001·68 cites·26 claims
- 1589US9758565B2Methods of treatment using CTLA4 mutant moleculesBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Sep 12, 2017·6 cites·14 claims
- 1684US8785398B2Methods of treatment using CTLA4 mutant moleculesPEACH ROBERT JAMES·Filed 2011·Granted Jul 22, 2014·6 cites·11 claims
- 1779US6413514B1Methods of using antibodies against human CD40BRISTOL MYERS SQUIBB CO·Filed 1999·Granted Jul 2, 2002·35 cites·10 claims
- 1878US7915395B2Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cellBRISTOL MYERS SQUIBB CO·Filed 2002·Granted Mar 29, 2011·10 cites·14 claims
- 1977US2021115107A1Methods of treatment using ctla4 moleculesBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 2076US6372215B1Monoclonal antibodies to human CD6BRISTOL MYERS SQUIBB CO·Filed 1998·Granted Apr 16, 2002·55 cites·16 claims
- 2170US2019185538A1Methods of treatment using ctla4 moleculesBRISTOL MYERS SQUIBB CO·Filed 2018·Application pending·0 cites
- 2268US10370428B2Methods of treatment using CTLA4 mutant moleculesBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Aug 6, 2019·0 cites·10 claims
- 2359US6114506AComposition and method for enhancing fibrinolysisGEN HOSPITAL CORP·Filed 1997·Granted Sep 5, 2000·14 cites·8 claims
- 2457US2004014171A1Soluble CTLA4 mutant molecules and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2003·Application pending·0 cites
- 2557US2010183612A1Methods of treatment using ctla4 mutant moleculesBRISTOL MYERS SQUIBB CO·Filed 2010·Application pending·0 cites
- 2651US2003219863A1Soluble CTLA4 mutant molecules and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2003·Application pending·0 cites
- 2750US7235631B2ICOS mutantsMAYO FOUNDATION·Filed 2002·Granted Jun 26, 2007·0 cites·9 claims
- 2849US2006264475A1Compounds, compositions and methods for inhibiting or treating hiv-1CYTOKINE PHARMASCIENCES INC·Filed 2006·Application pending·0 cites
- 2947US2004197934A1System for performing median partitioning as a method for diversity selection and identification of biologically active compoundsFiled 2004·Application pending·0 cites
- 3045US2005203150A1Compounds, compositions and methods for inhibiting or treating HIV-1Filed 2004·Application pending·0 cites
- 3139US5585404A3,5,3'-triiodothyronine receptor ligandsFiled 1995·Granted Dec 17, 1996·4 cites·3 claims
- 3236US2003119894A1Methods for treatment of cancer or neoplastic disease and for inhibiting growth of cancer cells and neoplastic cellsGEMIN X BIOTECHNOLOGIES INC·Filed 2001·Application pending·0 cites
- 3335US5567728AReceptor ligandsKAROBIO AB·Filed 1992·Granted Oct 22, 1996·2 cites·3 claims
- 3431US2003035816A1Soluble ctla4 mutant molecules and uses thereofFiled 1998·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →